Pascal Deschatelets
CIK 1657720 · Chief Scientific Officer · last filed 2026-05-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
1
Total Filings
86
Lifetime Open-Market Net
-$32.32M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Chief Scientific Officer | 0 | $41.03 | $0 | -$32.32M | 64 | 2026-05-14 |
Recent Filings · Page 6 of 9
86 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-03-10 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +6,500 | -$716.1K | EDGAR |
| 2023-02-22 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +8,691 | -$69.9K | EDGAR |
| 2023-02-14 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Tax (F) | −1,134 | -$58.1K | EDGAR |
| 2023-02-10 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +6,500 | -$604.0K | EDGAR |
| 2023-01-30 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Tax (F) | −832 | -$43.9K | EDGAR |
| 2023-01-24 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Tax (F) | −2,326 | -$121.1K | EDGAR |
| 2023-01-17 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +19,634 | $0 | EDGAR |
| 2023-01-10 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +6,500 | -$503.6K | EDGAR |
| 2022-12-30 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Exer (M) | +7,000 | $25.7K | EDGAR |
| 2022-12-12 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +6,500 | -$520.6K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.